UNSPSC 51294304: Ganaxolone

This classification denotes an antidepressant agent with the molecular formula C22H36O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98WI44OHIQ, chemically known as pregnan-20-one, 3-hydroxy-3-methyl-, (3alpha,5alpha)- but generally known as ganaxolone, which bears US NIH Compound Identifier 38022. European Medicines Agency schedules Ganaxolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07880MIG. The term GANAXOLONE is an International Non-Proprietary Name.

UNSPSC 51294304 Ganaxolone is a Commodity code nominally designating a specific anticonvulsant pharmaceutical, but recent state and local procurement activity under this code does not center on ganaxolone itself. Instead, issuing bodies are soliciting naloxone (an opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription program capabilities. The code appears to function as a catch-all pharmaceutical-procurement tag rather than a precise product classifier. State and local buyers using the code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP), reflecting a mix of direct county procurement, state-agency health programs, and multi-jurisdictional cooperative vehicles. The actual scope of work involves bulk purchase and delivery of emergency-response pharmaceuticals, competitive sourcing of generic drugs through authorized wholesaler channels, and exploratory contracting for innovative pharmacy benefit programs that bypass traditional pharmacy benefit manager intermediaries.

Activity concentrates in Florida and Texas, with multi-state reach through MMCAP's cooperative structure (serving Minnesota, Oregon, and participating jurisdictions). Recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due Jul 26, 2023), the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (due Apr 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers with a March 26, 2026 response deadline. The Seminole County contract involves quarterly deliveries with fixed-fee pricing and a two-year initial term plus one-year renewal option; the Texas RFI is exploratory, informing future procurement design; and the MMCAP RFP awards multiple contracts effective July 1, 2026, with pricing weighted at 75 percent competitiveness, 10 percent fixed pricing, and 5 percent compliance factors, requiring cGMP and Drug Supply Chain Security Act certification and $5 million in commercial general liability coverage.